LOGO
LOGO

Cell Therapeutics Says FDA Postpones ODAC Meeting To Review Pixantrone Due To Severe Weather Conditions - Quick Facts

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
rttnewslogo20mar2024

Cell Therapeutics Inc. or "CTI" (CTIC) announced that the United States Food and Drug Administration or the "FDA" informed CTI that due to severe weather conditions in the Washington, D.C. area, the FDA is postponing the Oncologic Drugs Advisory Committee or "ODAC" meeting that was to be held on Wednesday, February 10, 2010 to discuss the pixantrone New Drug Application or "NDA".

The FDA indicated that it plans to reschedule the meeting as soon as the FDA can determine a schedule that would allow them to reconvene the advisory panel. Also, the company said this meeting is an open public forum for the presentation and discussion of safety and efficacy information contained in the pixantrone NDA for the treatment of relapsed/refractory aggressive non-Hodgkin's lymphoma or NHL.

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update - Jun 08-12, 2026

June 12, 2026 17:14 ET
Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.